Vaxcyte, Inc.
PCVX
$30.61
-$1.68-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.04M | 32.66M | 28.56M | 22.99M | 21.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 226.22M | 180.79M | 162.17M | 139.92M | 152.98M |
| Operating Income | -226.22M | -180.79M | -162.17M | -139.92M | -152.98M |
| Income Before Tax | -166.57M | -140.72M | -137.08M | -103.12M | -128.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -166.57M | -140.72M | -137.08M | -103.12M | -128.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.57M | -140.72M | -137.08M | -103.12M | -128.70M |
| EBIT | -226.22M | -180.79M | -162.17M | -139.92M | -152.98M |
| EBITDA | -223.34M | -177.84M | -159.31M | -138.14M | -151.63M |
| EPS Basic | -1.22 | -1.04 | -1.01 | -0.83 | -1.10 |
| Normalized Basic EPS | -0.77 | -0.65 | -0.63 | -0.52 | -0.69 |
| EPS Diluted | -1.22 | -1.04 | -1.01 | -0.83 | -1.10 |
| Normalized Diluted EPS | -0.77 | -0.65 | -0.63 | -0.52 | -0.69 |
| Average Basic Shares Outstanding | 136.03M | 135.69M | 135.20M | 123.69M | 117.26M |
| Average Diluted Shares Outstanding | 136.03M | 135.69M | 135.20M | 123.69M | 117.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |